FDA-Drug2023-03-29Class II
JARDIANCE (Empagliflozin), 25 mg Tablets, packaged in a) 30-count (NDC0597-0153-30) and b) 90-count (NDC 0597-0153-90) bottles, Rx only, Marketed by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA and Eli Lilly and Company Indianapolis, IN 46285 USA
Boehringer Ingelheim Pharmaceuticals, Inc.
Hazard
Labeling: Label Mix-up
Sold states
Product was distributed nationwide within the United States and PR
Affected count
69,375 bottles
Manufactured in
900 Ridgebury Rd, N/A, Ridgefield, CT, United States
Products
JARDIANCE (Empagliflozin), 25 mg Tablets, packaged in a) 30-count (NDC0597-0153-30) and b) 90-count (NDC 0597-0153-90) bottles, Rx only, Marketed by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA and Eli Lilly and Company Indianapolis, IN 46285 USA
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0468-2023Don't want to check this manually?
We email you a Sunday digest of new federal recalls relevant to parents — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.
Get the Sunday Brief